Cancer Research AACR Conference on Molecular Diagnostics - 2008  Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

[Cancer Research 52, 5687-5692, October 15, 1992]
© 1992 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bhuyan, B. K.
Right arrow Articles by McGovren, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhuyan, B. K.
Right arrow Articles by McGovren, J. P.

Lethality, DNA Alkylation, and Cell Cycle Effects of Adozelesin (U-73975) on Rodent and Human Cells

B. K. Bhuyan1, K. S. Smith, E. G. Adams, G. L. Petzold and J. P. McGovren

Cancer and Infectious Diseases Research, The Upjohn Company, Kalamazoo, Michigan 49001

Adozelesin (U-73975) is an extremely potent cytotoxic agent which causes 90% lethality, after 2 h exposure in vitro, of Chinese hamster ovary and lung (CHO and V79), mouse melanoma (B16), and human ovarian carcinoma (A2780) cells at 0.33, 0.19, 0.2, and 0.025 ng/ml, respectively. Under similar conditions, Adriamycin and cisplatin had 90% lethality values in CHO cells of 150 ng/ml (=249 nM) and 6800 ng/ml (=2266 nM), respectively. The relative drug sensitivity of the cell lines (A2780 > V79, B16, CHO) was correlated to the relative amounts of [3H]adozelesin alkylated to DNA. The greater sensitivity of A2780 was due to (a) greater DNA alkylation at different drug doses and (b) greater intrinsic sensitivity of A2780 which resulted in greater cell kill at comparable DNA alkylation.

Phase specific toxicity studies show that adozelesin was least lethal to CHO cells in mitosis and very early G1. Lethality increased as cells progressed through G1 and was maximal in late G1 and early S. Mitotic cells had lower drug uptake and correspondingly less drug binding to DNA than G1 or S-phase cells. However, based on the amount of drug alkylated per µg of DNA, cells in M, G1, and S were equally sensitive. Therefore, the lower sensitivity of M-phase cells was due to lower drug uptake.

Adozelesin had three different effects on progression of CHO, V79, B16, and A2780 through the cell cycle: (a) slowed progression through S which resulted in significantly increasing the percentage of S-phase cells. This effect was transient; (b) cell progression was blocked in G2 for a long time period; (c) the response of the cell lines to the G2 block differed. CHO and V79 cells escaped G2 block by dividing and entered the diploid DNA cycle or did not undergo cytokinesis and became tetraploid. On the contrary, B16 and A2780 cells remained blocked in G2 and did not become tetraploid. Cell progression was inhibited in a similar manner when a synchronized population of M, G1, or S-phase cells were exposed to adozelesin.

1 To whom requests for reprints should be addressed.

Received 4/21/92. Accepted 8/ 4/92.




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
M.-B. Yin, Z.-R. Li, S. Cao, F. A. Durrani, R. G. Azrak, C. Frank, and Y. M. Rustum
Enhanced 7-Ethyl-10-hydroxycamptothecin (SN-38) Lethality by Methylselenocysteine Is Associated with Chk2 Phosphorylation at Threonine-68 and Down-Regulation of Cdc6 Expression
Mol. Pharmacol., July 1, 2004; 66(1): 153 - 160.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Bai and D. W. Goodrich
Different DNA lesions trigger distinct cell death responses in HCT116 colon carcinoma cells
Mol. Cancer Ther., May 1, 2004; 3(5): 613 - 620.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
P.-r. Cao, M. M. McHugh, T. Melendy, and T. Beerman
The DNA Minor Groove-alkylating Cyclopropylpyrroloindole Drugs Adozelesin and Bizelesin Induce Different DNA Damage Response Pathways in Human Colon Carcinoma HCT116 Cells
Mol. Cancer Ther., July 1, 2003; 2(7): 651 - 659.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
F. Blanchard, M. E. Rusiniak, K. Sharma, X. Sun, I. Todorov, M. M. Castellano, C. Gutierrez, H. Baumann, and W. C. Burhans
Targeted Destruction of DNA Replication Protein Cdc6 by Cell Death Pathways in Mammals and Yeast
Mol. Biol. Cell, May 1, 2002; 13(5): 1536 - 1549.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Weinberger, P. A. Trabold, M. Lu, K. Sharma, J. A. Huberman, and W. C. Burhans
Induction by Adozelesin and Hydroxyurea of Origin Recognition Complex-dependent DNA Damage and DNA Replication Checkpoints in Saccharomyces cerevisiae
J. Biol. Chem., December 10, 1999; 274(50): 35975 - 35984.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. J. Cobuzzi Jr., W. C. Burhans, and T. A. Beerman
Inhibition of Initiation of Simian Virus 40DNA Replication in Infected BSC-1 Cells by the DNA Alkylating Drug Adozelesin
J. Biol. Chem., August 16, 1996; 271(33): 19852 - 19859.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1992 by the American Association for Cancer Research.